{"id":40492,"date":"2024-11-08T20:39:48","date_gmt":"2024-11-09T03:39:48","guid":{"rendered":"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/"},"modified":"2024-11-08T20:39:48","modified_gmt":"2024-11-09T03:39:48","slug":"aloof-car-t-cell-remedy-accredited-for-leukemia","status":"publish","type":"post","link":"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/","title":{"rendered":"Aloof CAR T-Cell Remedy Accredited for Leukemia"},"content":{"rendered":"<div>\n<nav>    <a href=\"http:\/\/www.medpagetoday.com\/hematologyoncology\" tabindex=\"15.1\" itemprop=\"articleSection\">Oncology\/Hematology<\/a>    <span>&gt;<\/span>    <a href=\"http:\/\/www.medpagetoday.com\/hematologyoncology\/leukemia\" tabindex=\"15.2\">Leukemia<\/a>  <\/nav>\n<h2>&mdash;      Obecabtagene autoleucel has no requirement for a REMS program<\/h2>\n<p>                        by      <a href=\"https:\/\/www.medpagetoday.com\/people\/ii1250\/ian-ingram\">Ian Ingram<\/a>, <span>Managing Editor, <span>MedPage Today time<\/span><\/span>                            <span itemprop=\"datePublished\" content=\"November 8, 2024\">                                                                                        November 8, 2024                  <\/span>          <\/p>\n<\/p><\/div>\n<div id=\"js-main-content-region\" itemtype=\"http:\/\/schema.org\/articleBody\" itemid=\"#main-content-region\">\n<p>The FDA authorized obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults, the <a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-obecabtagene-autoleucel-adults-relapsed-or-refractory-b-cell-precursor-acute\" target=\"_blank\" rel=\"noopener\">agency offered<\/a> on Friday.<\/p>\n<p>Of point to, now not like other CAR T-cell therapies, the CD19-directed genetically modified autologous T-cell immunotherapy can occupy no requirement for a Threat Overview and Mitigation Technique (REMS) program.<\/p>\n<p>Approval used to be supported by the sole-arm, multicenter <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04404660\" target=\"_blank\" rel=\"noopener\">FELIX trial<\/a>which enrolled patients with relapsed or refractory CD19-certain B-cell ALL.<\/p>\n<p>Amongst the 65 patients evaluable for efficacy, a single infusion of obe-cel yielded a total remission (CR) rate of 42% (95% CI 29-54) at 3 months. Of these responders, the median length of CR reached 14.1 months. Overall, 63% of contributors finished a CR for the length of the gaze, including 12% with CR and incomplete hematologic recovery.<\/p>\n<p>&#8220;Aucatzyl is extremely active and would possibly per chance per chance additionally also be well managed, offering a beautiful likelihood-profit profile for B-ALL patients,&#8221; investigator Claire Roddie, MD, PhD, of the College College London Most cancers Institute, said in a <a href=\"https:\/\/autolus.gcs-web.com\/news-releases\/news-release-details\/autolus-therapeutics-announces-fda-approval-aucatzylr\" target=\"_blank\" rel=\"noopener\">assertion<\/a> from drugmaker Autolus Therapeutics. &#8220;Within the FELIX trial, Aucatzyl has shown prolonged-duration of time persistence and deep responses, which we mediate are severe for prolonged-duration of time remissions in B-ALL.&#8221;<\/p>\n<p>Patients enrolled in the half Ib\/II trial had to occupy relapsed following a outdated remission of a year or less, occupy relapsed or refractory ALL after as a minimal two outdated traces of therapy, or occupy disease that relapsed or used to be refractory 3 or extra months after allogeneic stem-cell transplantation.<\/p>\n<p>&#8220;Adult ALL is an awfully aggressive cancer, and there would possibly per chance be a excessive unmet scientific need that exists in the therapy of patients with this disease when they relapse, where historically they undergo from miserable outcomes,&#8221; investigator Elias Jabbour, MD, of the College of Texas MD Anderson Most cancers Center in Houston, said in an announcement.<\/p>\n<p>Love other CAR T-cell therapies, the <a href=\"https:\/\/www.autolus.com\/media\/aj4olbsd\/aucatzyl-pi-08-nov2024.pdf\" target=\"_blank\" rel=\"noopener\">drug&#8217;s labeling<\/a> has a boxed warning over dangers of cytokine free up syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and secondary T-cell malignancies. Within the FELIX trial, CRS came about in 75% of patients (with 3% grade 3 in severity), whereas ICANS came about in 24% (with 7% grade &ge;3). Overall, neurologic toxicities came about in 64% (12% grade &ge;3).<\/p>\n<p>Other authorized non-laboratory hostile occasions, going on in 20% or extra of contributors, included infections and bacterial infectious complications, musculoskeletal pain, fever, nausea, diarrhea, febrile neutropenia, hypotension, pain, fatigue, headache, encephalopathy, and hemorrhage.<\/p>\n<div>\n<ul>\n<li>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/clf1.medpagetoday.com\/media\/images\/author\/ianIngram_188.jpg\" alt=\"creator['full_name']\" width=\"50\" height=\"50\" previous-src=\"https:\/\/clf1.medpagetoday.com\/media\/images\/author\/ianIngram_188.jpg\">                            <\/p>\n<p><a href=\"https:\/\/www.medpagetoday.com\/people\/ii1250\/ian-ingram\">Ian Ingram<\/a> is Managing Editor at MedPage Today time and helps duvet oncology for the positioning.   <\/p>\n<\/li>\n<\/ul><\/div>\n<\/p><\/div>\n<p><a href=\"https:\/\/www.medpagetoday.com\/hematologyoncology\/leukemia\/112823\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Oncology\/Hematology &gt; Leukemia &mdash; Obecabtagene autoleucel has no requirement for a REMS program by Ian&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40493,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Aloof CAR T-Cell Remedy Accredited for Leukemia - CBS26 Arizona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aloof CAR T-Cell Remedy Accredited for Leukemia - CBS26 Arizona\" \/>\n<meta property=\"og:description\" content=\"Oncology\/Hematology &gt; Leukemia &mdash; Obecabtagene autoleucel has no requirement for a REMS program by Ian...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/\" \/>\n<meta property=\"og:site_name\" content=\"CBS26 Arizona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CBSNews\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-09T03:39:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/clf1.medpagetoday.com\/media\/images\/author\/ianIngram_188.jpg\" \/>\n<meta name=\"author\" content=\"cbs26.com\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@CBSNews\" \/>\n<meta name=\"twitter:site\" content=\"@CBSNews\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"cbs26.com\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/\"},\"author\":{\"name\":\"cbs26.com\",\"@id\":\"https:\/\/cbs26.com\/#\/schema\/person\/6f199387dd167b788a14f8b99f8ff352\"},\"headline\":\"Aloof CAR T-Cell Remedy Accredited for Leukemia\",\"datePublished\":\"2024-11-09T03:39:48+00:00\",\"dateModified\":\"2024-11-09T03:39:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/\"},\"wordCount\":451,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cbs26.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cbs26.com\/wp-content\/uploads\/2024\/11\/40492-aloof-car-t-cell-remedy-accredited-for-leukemia.jpg\",\"articleSection\":[\"Health\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/\",\"url\":\"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/\",\"name\":\"Aloof CAR T-Cell Remedy Accredited for Leukemia - CBS26 Arizona\",\"isPartOf\":{\"@id\":\"https:\/\/cbs26.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cbs26.com\/wp-content\/uploads\/2024\/11\/40492-aloof-car-t-cell-remedy-accredited-for-leukemia.jpg\",\"datePublished\":\"2024-11-09T03:39:48+00:00\",\"dateModified\":\"2024-11-09T03:39:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/#primaryimage\",\"url\":\"https:\/\/cbs26.com\/wp-content\/uploads\/2024\/11\/40492-aloof-car-t-cell-remedy-accredited-for-leukemia.jpg\",\"contentUrl\":\"https:\/\/cbs26.com\/wp-content\/uploads\/2024\/11\/40492-aloof-car-t-cell-remedy-accredited-for-leukemia.jpg\",\"width\":1280,\"height\":720,\"caption\":\"Aloof CAR T-Cell Remedy Accredited for Leukemia\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cbs26.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aloof CAR T-Cell Remedy Accredited for Leukemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cbs26.com\/#website\",\"url\":\"https:\/\/cbs26.com\/\",\"name\":\"CBS26 Arizona\",\"description\":\"The Spirit of Arizona\",\"publisher\":{\"@id\":\"https:\/\/cbs26.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cbs26.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cbs26.com\/#organization\",\"name\":\"CBS26 Arizona\",\"url\":\"https:\/\/cbs26.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/cbs26.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cbs26.com\/wp-content\/uploads\/2023\/12\/cbs26.fw_-1-e1703104627272.png\",\"contentUrl\":\"https:\/\/cbs26.com\/wp-content\/uploads\/2023\/12\/cbs26.fw_-1-e1703104627272.png\",\"width\":296,\"height\":96,\"caption\":\"CBS26 Arizona\"},\"image\":{\"@id\":\"https:\/\/cbs26.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/CBSNews\/\",\"https:\/\/x.com\/CBSNews\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cbs26.com\/#\/schema\/person\/6f199387dd167b788a14f8b99f8ff352\",\"name\":\"cbs26.com\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/cbs26.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e5c693e6a74bdbc1461a75db724fe465?s=96&d=mm&r=r\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e5c693e6a74bdbc1461a75db724fe465?s=96&d=mm&r=r\",\"caption\":\"cbs26.com\"},\"sameAs\":[\"http:\/\/cbs26.com\"],\"url\":\"https:\/\/cbs26.com\/index.php\/author\/cbs26-com\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aloof CAR T-Cell Remedy Accredited for Leukemia - CBS26 Arizona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/","og_locale":"en_GB","og_type":"article","og_title":"Aloof CAR T-Cell Remedy Accredited for Leukemia - CBS26 Arizona","og_description":"Oncology\/Hematology &gt; Leukemia &mdash; Obecabtagene autoleucel has no requirement for a REMS program by Ian...","og_url":"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/","og_site_name":"CBS26 Arizona","article_publisher":"https:\/\/www.facebook.com\/CBSNews\/","article_published_time":"2024-11-09T03:39:48+00:00","og_image":[{"url":"https:\/\/clf1.medpagetoday.com\/media\/images\/author\/ianIngram_188.jpg"}],"author":"cbs26.com","twitter_card":"summary_large_image","twitter_creator":"@CBSNews","twitter_site":"@CBSNews","twitter_misc":{"Written by":"cbs26.com","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/#article","isPartOf":{"@id":"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/"},"author":{"name":"cbs26.com","@id":"https:\/\/cbs26.com\/#\/schema\/person\/6f199387dd167b788a14f8b99f8ff352"},"headline":"Aloof CAR T-Cell Remedy Accredited for Leukemia","datePublished":"2024-11-09T03:39:48+00:00","dateModified":"2024-11-09T03:39:48+00:00","mainEntityOfPage":{"@id":"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/"},"wordCount":451,"commentCount":0,"publisher":{"@id":"https:\/\/cbs26.com\/#organization"},"image":{"@id":"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/#primaryimage"},"thumbnailUrl":"https:\/\/cbs26.com\/wp-content\/uploads\/2024\/11\/40492-aloof-car-t-cell-remedy-accredited-for-leukemia.jpg","articleSection":["Health"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/","url":"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/","name":"Aloof CAR T-Cell Remedy Accredited for Leukemia - CBS26 Arizona","isPartOf":{"@id":"https:\/\/cbs26.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/#primaryimage"},"image":{"@id":"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/#primaryimage"},"thumbnailUrl":"https:\/\/cbs26.com\/wp-content\/uploads\/2024\/11\/40492-aloof-car-t-cell-remedy-accredited-for-leukemia.jpg","datePublished":"2024-11-09T03:39:48+00:00","dateModified":"2024-11-09T03:39:48+00:00","breadcrumb":{"@id":"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/#primaryimage","url":"https:\/\/cbs26.com\/wp-content\/uploads\/2024\/11\/40492-aloof-car-t-cell-remedy-accredited-for-leukemia.jpg","contentUrl":"https:\/\/cbs26.com\/wp-content\/uploads\/2024\/11\/40492-aloof-car-t-cell-remedy-accredited-for-leukemia.jpg","width":1280,"height":720,"caption":"Aloof CAR T-Cell Remedy Accredited for Leukemia"},{"@type":"BreadcrumbList","@id":"https:\/\/cbs26.com\/index.php\/2024\/11\/08\/aloof-car-t-cell-remedy-accredited-for-leukemia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cbs26.com\/"},{"@type":"ListItem","position":2,"name":"Aloof CAR T-Cell Remedy Accredited for Leukemia"}]},{"@type":"WebSite","@id":"https:\/\/cbs26.com\/#website","url":"https:\/\/cbs26.com\/","name":"CBS26 Arizona","description":"The Spirit of Arizona","publisher":{"@id":"https:\/\/cbs26.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cbs26.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/cbs26.com\/#organization","name":"CBS26 Arizona","url":"https:\/\/cbs26.com\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/cbs26.com\/#\/schema\/logo\/image\/","url":"https:\/\/cbs26.com\/wp-content\/uploads\/2023\/12\/cbs26.fw_-1-e1703104627272.png","contentUrl":"https:\/\/cbs26.com\/wp-content\/uploads\/2023\/12\/cbs26.fw_-1-e1703104627272.png","width":296,"height":96,"caption":"CBS26 Arizona"},"image":{"@id":"https:\/\/cbs26.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/CBSNews\/","https:\/\/x.com\/CBSNews"]},{"@type":"Person","@id":"https:\/\/cbs26.com\/#\/schema\/person\/6f199387dd167b788a14f8b99f8ff352","name":"cbs26.com","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/cbs26.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e5c693e6a74bdbc1461a75db724fe465?s=96&d=mm&r=r","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e5c693e6a74bdbc1461a75db724fe465?s=96&d=mm&r=r","caption":"cbs26.com"},"sameAs":["http:\/\/cbs26.com"],"url":"https:\/\/cbs26.com\/index.php\/author\/cbs26-com\/"}]}},"_links":{"self":[{"href":"https:\/\/cbs26.com\/index.php\/wp-json\/wp\/v2\/posts\/40492"}],"collection":[{"href":"https:\/\/cbs26.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cbs26.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cbs26.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cbs26.com\/index.php\/wp-json\/wp\/v2\/comments?post=40492"}],"version-history":[{"count":0,"href":"https:\/\/cbs26.com\/index.php\/wp-json\/wp\/v2\/posts\/40492\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cbs26.com\/index.php\/wp-json\/wp\/v2\/media\/40493"}],"wp:attachment":[{"href":"https:\/\/cbs26.com\/index.php\/wp-json\/wp\/v2\/media?parent=40492"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cbs26.com\/index.php\/wp-json\/wp\/v2\/categories?post=40492"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cbs26.com\/index.php\/wp-json\/wp\/v2\/tags?post=40492"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}